Multiple Myeloma Clinical Trials in Seattle, Washington
25 recruitingSeattle, Washington
Showing 1–20 of 25 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Collection of Tissue Samples for Cancer Research
NeoplasmsMultiple MyelomaMyelodysplastic Syndrome+1 more
National Cancer Institute (NCI)5,000 enrolled17 locationsNCT00900198
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting
Phase 2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting
Phase 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Opna Bio LLC130 enrolled11 locationsNCT06433947
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie135 enrolled26 locationsNCT06896916
Recruiting
Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
Kite, A Gilead Company450 enrolled124 locationsNCT06413498
Recruiting
Phase 1Phase 2
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07181941
Recruiting
Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company187 enrolled19 locationsNCT06153251
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 2
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Multiple Myeloma
University of Alabama at Birmingham300 enrolled10 locationsNCT05231629
Recruiting
Not Applicable
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Multiple MyelomaRelapsed Hematologic Malignancy
Pack Health100 enrolled1 locationNCT05956457
Recruiting
Not Applicable
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Multiple MyelomaRefractory Multiple Myeloma
Pack Health50 enrolled2 locationsNCT05053607
Recruiting
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Multiple MyelomaMultiple Myeloma Without Mention of Remission
All4Cure450 enrolled1 locationNCT06149910